Literature DB >> 32128678

Establishment of a Genomic-Clinicopathologic Nomogram for Predicting Early Recurrence of Hepatocellular Carcinoma After R0 Resection.

Bin Yu1, Han Liang1, Qifa Ye1,2, Yanfeng Wang3.   

Abstract

BACKGROUND: A high rate of postoperative recurrence, especially early recurrence (ER) occurring within 1 year, seriously impedes patients with hepatocellular carcinoma (HCC) from achieving long-term survival. This study aimed to establish a genomic-clinicopathologic nomogram for precisely predicting ER in HCC patients after R0 resection.
METHODS: Two reliable datasets from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases were selected as the training and validation cohorts, respectively. The prognostic genes related to ER were screened out by univariate Cox regression analysis and differential expression analysis. The gene-based prognostic index was constructed using LASSO and Cox regression analyses, and its independent prognostic value was assessed by Kaplan-Meier and multivariate Cox analyses. Gene set enrichment analysis (GSEA) was performed to explore the biological pathways related to the prognostic index. Finally, the nomogram integrating all the independent prognostic factors was established and comprehensively evaluated by calibration plots, the C-index, receiver operating characteristic curves, and decision curve analysis.
RESULTS: Nine dysregulated and prognostic genes related to ER (ZNF131, TATDN2, TXN, DDX55, KPNA2, ZNF30, TIMELESS, SFRP1, and COLEC11) were identified (all P < 0.05). The prognostic index model based on the 9 genes was successfully constructed using the TCGA cohort and showed a certain capability to discriminate the ER group from the non-ER group (P < 0.05) and good independent prognostic value in terms of predicting poor early recurrence-free survival (P < 0.05). Eight biological pathways significantly related to ER were identified by GSEA, such as "cell cycle", "homologous recombination" and "p53 signaling pathway." The genomic-clinicopathologic nomogram integrating the 9-gene-based prognostic index and TNM stage displayed significantly higher predictive accuracy and clinical application value than that of TNM stage model both in the training and validation cohorts (all P < 0.05).
CONCLUSIONS: The novel genomic-clinicopathologic nomogram may be a convenient and powerful tool for accurately predicting ER in HCC patients after R0 resection.

Entities:  

Keywords:  Biomarker; Early recurrence; Hepatocellular carcinoma; Nomogram; Recurrence-free survival

Mesh:

Substances:

Year:  2020        PMID: 32128678     DOI: 10.1007/s11605-020-04554-1

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  39 in total

Review 1.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; María Reig; Jordi Bruix
Journal:  Lancet       Date:  2018-01-05       Impact factor: 79.321

Review 2.  Classification and staging of hepatocellular carcinoma: an aid to clinical decision-making.

Authors:  Benyam D Addissie; Lewis R Roberts
Journal:  Clin Liver Dis       Date:  2015-05       Impact factor: 6.126

3.  Factors predicting early recurrence after surgical resection of hepatocellular carcinoma.

Authors:  Yao-Ming Zhang; Zhen-Tao Zhou; Gao-Min Liu
Journal:  J Hepatol       Date:  2018-12-20       Impact factor: 25.083

4.  Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection.

Authors:  Anthony W H Chan; Jianhong Zhong; Sarah Berhane; Hidenori Toyoda; Alessandro Cucchetti; KeQing Shi; Toshifumi Tada; Charing C N Chong; Bang-De Xiang; Le-Qun Li; Paul B S Lai; Vincenzo Mazzaferro; Marta García-Fiñana; Masatoshi Kudo; Takashi Kumada; Sasan Roayaie; Philip J Johnson
Journal:  J Hepatol       Date:  2018-09-18       Impact factor: 25.083

Review 5.  Molecular and histological correlations in liver cancer.

Authors:  Julien Calderaro; Marianne Ziol; Valérie Paradis; Jessica Zucman-Rossi
Journal:  J Hepatol       Date:  2019-06-10       Impact factor: 25.083

6.  A nomogram to predict early postoperative recurrence of hepatocellular carcinoma with portal vein tumour thrombus after R0 liver resection: A large-scale, multicenter study.

Authors:  Xiu-Ping Zhang; Zhen-Hua Chen; Teng-Fei Zhou; Le-Qun Li; Min-Shan Chen; Tian-Fu Wen; Jie Shi; Wei-Xing Guo; Meng-Chao Wu; Wan Yee Lau; Shu-Qun Cheng
Journal:  Eur J Surg Oncol       Date:  2019-04-03       Impact factor: 4.424

7.  Identification and validation of a potent multi-mRNA signature for the prediction of early relapse in hepatocellular carcinoma.

Authors:  Jie Cai; Ying Tong; Lifeng Huang; Lei Xia; Han Guo; Hailong Wu; Xiaoni Kong; Qiang Xia
Journal:  Carcinogenesis       Date:  2019-07-20       Impact factor: 4.944

Review 8.  Design and endpoints of clinical trials in hepatocellular carcinoma.

Authors:  Josep M Llovet; Adrian M Di Bisceglie; Jordi Bruix; Barnett S Kramer; Riccardo Lencioni; Andrew X Zhu; Morris Sherman; Myron Schwartz; Michael Lotze; Jayant Talwalkar; Gregory J Gores
Journal:  J Natl Cancer Inst       Date:  2008-05-13       Impact factor: 13.506

Review 9.  Epidemiology and Management of Hepatocellular Carcinoma.

Authors:  Laura Kulik; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2018-10-24       Impact factor: 22.682

Review 10.  Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma.

Authors:  Clifford Akateh; Sylvester M Black; Lanla Conteh; Eric D Miller; Anne Noonan; Eric Elliott; Timothy M Pawlik; Allan Tsung; Jordan M Cloyd
Journal:  World J Gastroenterol       Date:  2019-07-28       Impact factor: 5.742

View more
  6 in total

1.  Novel Plasma Proteomic Biomarkers for Early Identification of Induction Chemotherapy Beneficiaries in Locoregionally Advanced Nasopharyngeal Carcinoma.

Authors:  Shan-Qiang Zhang; Su-Ming Pan; Shu-Zhen Lai; Hui-Jing Situ; Jun Liu; Wen-Jie Dai; Si-Xian Liang; Li-Qing Zhou; Qi-Qi Lu; Pei-Feng Ke; Fan Zhang; Hai-Bin Chen; Ji-Cheng Li
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

2.  Reproductive history and blood cell DNA methylation later in life: the Young Finns Study.

Authors:  Emily W Harville; Pashupati P Mishra; Mika Kähönen; Emma Raitoharju; Saara Marttila; Olli Raitakari; Terho Lehtimäki
Journal:  Clin Epigenetics       Date:  2021-12-20       Impact factor: 6.551

3.  Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period.

Authors:  Masaki Kaibori; Kazuko Sakai; Hideyuki Matsushima; Hisashi Kosaka; Kosuke Matsui; Marco A De Velasco; Mitsugu Sekimoto; Kazuto Nishio
Journal:  Hepatol Int       Date:  2022-01-01       Impact factor: 6.047

4.  A Practical Nomogram and Risk Stratification System Predicting the Cancer-Specific Survival for Patients With Advanced Hepatocellular Carcinoma.

Authors:  Dashuai Yang; Yang Su; Fangrui Zhao; Chen Chen; Kailiang Zhao; Xiangyun Xiong; Youming Ding
Journal:  Front Oncol       Date:  2022-07-12       Impact factor: 5.738

5.  DDX55 promotes hepatocellular carcinoma progression by interacting with BRD4 and participating in exosome-mediated cell-cell communication.

Authors:  Bin Yu; Shujun Zhou; Dakun Long; Yuxiang Ning; Hanlin Yao; Encheng Zhou; Yanfeng Wang
Journal:  Cancer Sci       Date:  2022-06-10       Impact factor: 6.518

6.  KPNA2-Associated Immune Analyses Highlight the Dysregulation and Prognostic Effects of GRB2, NRAS, and Their RNA-Binding Proteins in Hepatocellular Carcinoma.

Authors:  Xiuzhi Zhang; Jialing Zhang; Fenglan Gao; Shasha Fan; Liping Dai; Jinzhong Zhang
Journal:  Front Genet       Date:  2020-10-26       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.